Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovascular disease, enabling medical practitioners to treat patients and improve their lives.

Guangdong Maijinjia Biotechnology Co., Ltd., established on 2019-08-14, Business scope includes drug research and development(human stem cells,Except for genetic diagnosis and treatment technology);Pharmaceutical Research Services;Medical Research and Experimental Development(human stem cells,Except for genetic diagnosis and treatment technology);Health Sciences Program Research,to develop;Biomedical Technology Research(human stem cells,Except for genetic diagnosis and treatment technology);Human Science Research Achievement Transfer Service;Medical Technology Consulting,communication service;Medical technology transfer service;Health Sciences Program Research Transfer;Technology Promotion of Research Results of Health Science Projects;Biotechnology Extension Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Development Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Consulting,communication service(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Transfer Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Manufacturing of chemical raw materials;pharmaceutical preparations:slow release,Controlled release,target,New dosage forms of new technologies such as transdermal absorption,new product production;Manufacturing of chemical preparations;Biopharmaceutical Manufacturing;Drug retail;Chemicals,Biological product(Contains vaccine)wholesale;

Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif M��ller on July 1, 2009 and is headquartered in Vejle, Denmark.

Rijk Zwaan Zaadteelt en Zaadhandel BV develops and distributes vegetables and seeds. The company was founded in 1932 and is headquartered in de Lier, the Netherlands.

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Onconetics Pharmaceuticals, Inc. is an early-stage pharmaceutical startup based in San Francisco, California. Onconetics engages in research and drug development for the emerging and highly sought-after field of personalized medicine in order to develop treatments for cancer and other genetic disorders. It combines well-established gene therapy techniques with pioneering research to create novel therapeutic outcomes that seek to change the highly invasive, costly, and uncertain nature of traditional therapies. Onconetics aims to create simpler, more versatile personalized therapies for cancer and genetic disorders that pose little or no risk to the patient and their quality of life, while pushing the frontiers of our understanding of the microscopic world.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

GlobalFoundries (also known as GF) is an American semiconductor foundry headquartered in Santa Clara, California, United States. GlobalFoundries was created by the divestiture of the manufacturing arm of Advanced Micro Devices (AMD). The Emirate of Abu Dhabi is the owner of the company through its subsidiary Advanced Technology Investment Company (ATIC).

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud, and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

Combined Therapeutics Inc. (CTx) is a pre-clinical-stage biotech in the game-changing segment of cancer research that is immunotherapy. The company is converging nanomedicine and biotechnology to enhance the tumoral cells and the tumoral microenvironment targeting. Combined Therapeutics Inc. (or CTx) is an immuno-oncology spin-out of the highly successful and entrepreneurial Langer-Lab at the Massachusetts Institute of Technology (MIT). The first word of their name “Combined” emanates from the fact that they combine their technology with existing immuno-oncology products for a breakthrough in immunotherapy and better patients healthcare.

genebang.com is an innovative enterprise in the field of biotechnology. Their services include virome analysis of human samples, virome analysis of animal samples, and environmental virome sample analysis. They conduct development and transformation research in the field of virology.

Mirus Bio LLC is an American private company located in Madison, WI. The firm develops biomimetic and cell-adaptive lipid-polymer nano complexes for nucleic acid delivery. It was founded in 1995 by Vladimir Budker, Jon A. Wolff and James E. Hagstrom. Dale Gordon is the CEO, in this role since 2021.\nThe company says this about itself: Mirus Bio is a leading provider of transfection products for the biopharmaceutical and research industries, offering best-in-class reagents for cell and gene therapy, recombinant protein expression, and stem cell applications. An original pioneer in nucleic acid delivery, the company has been enabling scientific research and innovation for more than two decades. In 2021, Mirus introduced TransIT-VirusGEN? GMP Transfection Reagent and Kits to address the commercial biopharmaceutical and cell and gene therapy markets with support for viral vector manufacturing (AAV and LV).

ReveraGen BioPharma is a small clinical-stage drug development company with a focus on developing therapeutics for Duchenne muscular dystrophy. they run under a venture philanthropy model, through collaborations and partnerships with non-profit foundations and government agencies in both the US and the EU. As such, we keep the focus on stakeholders rather than stockholders.